{"created":"2023-05-15T16:49:23.630088+00:00","id":26830,"links":{},"metadata":{"_buckets":{"deposit":"a2365ead-b180-4f08-b8a9-78c653b5ed4b"},"_deposit":{"created_by":6,"id":"26830","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"26830"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00026830","sets":["35:36"]},"author_link":["118901","118900","118899"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-05-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageStart":"art. no. 869","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"Viruses"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease caused by the SFTS virus (SFTSV). SFTS is mainly prevalent in East Asia. It has a mortality rate of up to 30%, and there is no approved treatment against the disease. In this study, we evaluated the effect of loperamide, an antidiarrheal and antihyperalgesic agent, on the propagation of SFTSV in a cell culture system. \nMethods: SFTSV-infected human cell lines were exposed to loperamide, and viral titers were evaluated. To clarify the mode of action of loperamide, several chemical compounds having shared targets with loperamide were used. Calcium imaging was also performed to understand whether loperamide treatment affected calcium influx.\nResults: Loperamide inhibited SFTSV propagation in several cell lines. It inhibited SFTSV in the post-entry step and restricted calcium influx into the cell. Furthermore, nifedipine, a calcium channel inhibitor, also blocked post-entry step of SFTSV infection.\nConclusions: Loperamide inhibits SFTSV propagation mainly by restraining calcium influx into the cytoplasm. This indicates that loperamide, a Food and Drug Administration (FDA)-approved drug, has the potential for being used as a treatment option against SFTS. ","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Viruses, 13(5), art. no. 869; 2021","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.3390/v13050869","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"19994915","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Urata, Shuzo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yasuda, Jiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Iwasaki, Masaharu"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-04"}],"displaytype":"detail","filename":"Viruses13_869.pdf","filesize":[{"value":"1.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Viruses13_869.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/26830/files/Viruses13_869.pdf"},"version_id":"5100c4d5-8792-4e20-8cdd-c94e80227d19"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"severe fever with thrombocytopenia syndrome virus","subitem_subject_scheme":"Other"},{"subitem_subject":"antiviral","subitem_subject_scheme":"Other"},{"subitem_subject":"loperamide","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Loperamide Inhibits Replication of Severe Fever with Thrombocytopenia Syndrome Virus","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Loperamide Inhibits Replication of Severe Fever with Thrombocytopenia Syndrome Virus"}]},"item_type_id":"2","owner":"6","path":["36"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-04"},"publish_date":"2021-11-04","publish_status":"0","recid":"26830","relation_version_is_last":true,"title":["Loperamide Inhibits Replication of Severe Fever with Thrombocytopenia Syndrome Virus"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-05-15T20:10:11.242380+00:00"}